单倍体移植中HLA表位错配与复发减少及植入延迟相关
该单中心回顾性研究分析了148例接受外周血T细胞充足单倍体造血干细胞移植联合高剂量移植后环磷酰胺的患者,采用HLAMatchmaker方法量化HLA表位错配。结果显示,移植物抗宿主方向HLA II类表位错配较高与复发风险显著降低及无复发生存改善相关,而宿主抗移植物方向HLA II类表位错配较高与中性粒细胞和血小板植入时间延长相关。
要点
- 移植物抗宿主方向HLA II类表位错配每增加1个,复发风险调整HR为0.952(P=0.002)。
- 移植物抗宿主方向HLA II类表位错配每增加1个,无复发生存调整HR为0.974(P=0.020)。
- 宿主抗移植物方向HLA II类表位错配较高与中性粒细胞和血小板植入延迟相关。
核心结论
- 在外周血单倍体移植患者中,移植物抗宿主方向HLA表位错配增加与复发风险的保护效应相关,而宿主抗移植物方向表位错配增加与计数恢复时间延迟的负面效应相关。
- 基于HLAMatchmaker的HLA表位错配是预测单倍体移植临床结局的新策略。
研究设计与样本
- 单中心回顾性分析148例接受外周血T细胞充足单倍体造血干细胞移植联合移植后环磷酰胺的患者。
- 采用基于HLAMatchmaker的方法量化HLA表位错配,并按类别和方向进行分层。
主要发现
- 每对患者-供者移植物抗宿主方向错配表位总数范围为0至51(中位数24),宿主抗移植物方向为0至47(中位数24)。
- 移植物抗宿主方向HLA II类表位错配较高与复发风险显著降低相关(调整HR 0.952/每个错配表位;P=0.002)。
- 移植物抗宿主方向HLA II类表位错配较高与无复发生存改善相关(调整HR 0.974/每个错配表位;P=0.020)。
- 宿主抗移植物方向HLA II类表位错配较高与中性粒细胞植入时间延长相关(调整HR 0.974/每个错配表位;P=0.013)。
- 宿主抗移植物方向HLA II类表位错配较高与血小板植入时间延长相关(调整HR 0.961/每个错配表位;P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA disparity is traditionally measured at the antigen or allele level, and its impact on haploidentical hematopoietic cell transplantation (haplo-HCT) with high-dose posttransplant cyclophosphamide (PTCy) is unclear. To the best of our knowledge, the relationship between HLA eplet-derived epitope mismatch (EM) and clinical outcome has not been examined in haplo-HCT. We retrospectively analyzed 148 patients who received a peripheral blood, T-cell-replete haplo-HCT with PTCy at a single center. HLA EM was quantified using an HLAMatchmaker-based method and was stratified by class and vector. The primary outcome was incidence of relapse. The total number of mismatched epitopes (MEs) per patient-donor pair in our patient population ranged from 0 to 51 (median, 24) in the graft-versus-host (GVH) direction and 0 to 47 (median, 24) in the host-versus-graft (HVG) direction. Higher HLA class II EM in the GVH direction was associated with a significantly reduced risk of relapse (adjusted hazard ratio [HR], 0.952 per ME; P = .002) and improved relapse-free survival (adjusted HR, 0.974 per ME; P = .020). Higher HLA class II EM in the HVG direction was associated with longer time to neutrophil (adjusted HR, 0.974 per ME; P = .013) and platelet (adjusted HR, 0.961 per ME; P = .001) engraftment. In peripheral blood haplo-HCT patients, increased HLA EM was associated with a protective effect on the risk of relapse in the GVH direction but a negative effect on time to count recovery in the HVG direction. HLA EM based on the HLA Matchmaker represents a novel strategy to predict clinical outcome in haplo-HCT.
引用
- Rimando J, Slade M, DiPersio JF, et al. HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Adv. 2018. PMID: 30563883. doi:10.1182/bloodadvances.2018025437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。